Karl Stemtrowsky

Karl Stemtrowsky:

Pharmacyclics Inc. (PCYC) reported trial results of the first Phase III study (RESONATE, PCYC-1112-CA), a head-to-head comparison of IMBRUVICA(R) (ibrutinib) versus ofatumumab in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (a slow-growing lymphoma in which too many immature white blood cells cause lymph nodes to become larger than normal).According to PCYC, patients receiving IMBRUVICA realized a significant improvement in progression free survival, overall survival and overall response rate as compared to patients receiving ofatumumab. http://finance.crwe-pr.com/2014/06/01/trials-positive-data-advaxis-nasdaqadxs-cervical-cancer-abbvie-nyseabbv-and-pharmacyclics-nasdaqpcyc-chronic-lymphoma-leukemia/